SHLD3

Across TCGA pan-cancer cohorts, SHLD3 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of SHLD3’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SHLD3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SHLD3 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

LIHC, BLCA, and KIRC are the cancer types where SHLD3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SHLD3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+0.776	<.001	9	view →
BLCA	Male	III,IV	+0.704	<.001	8	view →
KIRC	All	IV	+0.296	.002	8	view →
THCA	Female	All	−0.331	<.001	7	view →
UCEC	All	All	+0.389	.005	6	view →
BRCA	All	II,III,IV	+0.346	<.001	6	view →
HNSC	All	IV	+0.345	.002	5	view →
CHOL	All	All	+1.386	<.001	3	view →
STAD	Female	All	+0.815	.002	3	view →
ESCA	Female	All	+0.533	.016	2	view →
KICH	All	All	−0.351	.023	1	view →
LUAD	All	All	+0.233	.011	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

SHLD3–LIHC

Open the LIHC breakdown →